NICE

When should progression-free survival be used as a surrogate for overall survival in oncology? Uneven reporting of results – different definitions and methods of analysis, lack of rigour in applying methodology – make progress difficult.

This blog post discusses the role of social value judgements in NICE technology appraisals, focusing on the recent appraisal of dinutuximab beta for high-risk neuroblastoma.

A new OHE Research Paper sets out an agenda for the development of methods to estimate cost-effectiveness thresholds in the NHS.

We conducted a literature review in order to identify whether long-term cancer survivors’ quality of life is comparable to that of the general population.

Just published in Social Science & Medicine: a review of stated preferences examining the extent of support for an end of life premium.

A new OHE report discusses NICE’s introduction of a cost-effectiveness threshold to appraise ultra-orphan drugs.

A new paper titled “Challenges in Valuing Temporary Health States for Economic Evaluation: A Review of Empirical Applications of the Chained Time Trade-Off Method” has been published in Value in Health.

This report analyses patient access in the UK to new medicines authorised via the centralised procedure between 2011 and 2016.

In this blog we (1) summarise the current status of the EQ-5D-5L value set for England; (2) highlight NICE’s recent statement on the values to be used in the reference case; (3) briefly explain why there are differences between the EQ-5D-3L and EQ-5D-5L; and (4) discuss why those differences might be important. We then (5) explain the next steps, including an independent quality assurance of the value set, and (6) provide an overview of current research projects underway at OHE to provide further evidence on the implications of new value sets for HTA and other uses.

The presentations delivered by OHE at the HTAi Annual Meeting, June 2017, are available in this post.

Pages

Subscribe to RSS - NICE